Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination ...

AstraZeneca (NASDAQ:AZN) announced Tuesday that its FDA-approved breast cancer therapy ... alterations as its dual primary endpoints. The drug combination's tolerability profile was largely ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to ...

Bloomberg / Contributor / Getty Images A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a ...

(Sharecast News) - AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve survival. The FTSE 100 pharmaceutical giant said the ...

June 18 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Tuesday its breast cancer drug, Truqap ... in combination with a placebo. The study failed to achieve its goals in both the overall ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...